首页> The Journal of urology> Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.

Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Yair,Lotan

第一单位： Departments of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.

作者： Yair,Lotan ^[1] ; Brant A,Inman ^[2] ; Leah Gerber,Davis ^[3] ; Wassim,Kassouf ^[4] ; Edward,Messing ^[5] ; Siamak,Daneshmand ^[6] ; Daniel,Canter ^[7] ; H Tony,Marble ^[8] ; Ajith M,Joseph ^[8] ; Susan,Jewell ^[8] ; Stephen A,Boorjian ^[9]

作者单位： Departments of Urology, University of Texas Southwestern Medical Center, Dallas, Texas. ^[1] Division of Urology, Duke University Medical Center, Durham, North Carolina. ^[2] Division of Urology, Duke University Medical Center, Durham, North Carolina.;Duke Cancer Center Biostatistics, Duke University Medical Center, Durham, North Carolina. ^[3] McGill University Health Center, Montreal, Quebec, Canada. ^[4] University of Rochester, Rochester, New York. ^[5] University of Southern California, Los Angeles, California. ^[6] Ochsner Medical Center, New Orleans, Louisiana. ^[7] Abbott Molecular Inc., Des Plaines, Illinois. ^[8] Mayo Clinic, Rochester, Minnesota. ^[9]

关键词 BCG vaccine carcinoma in situ fluorescence in situ hybridization local neoplasm recurrence urinary bladder neoplasms